Literature DB >> 1637543

Conservative endoscopic surgery in inverted papilloma. Preliminary report.

R H Kamel1.   

Abstract

Inverted papilloma is noted for recurrence and occasional association with malignancy, leading most authors to recommend lateral rhinotomy as the initial surgical approach in all cases; however, conservative surgery has been reported to be effective in selective cases. Endoscopic control was used in the surgical treatment of three cases of inverted papilloma. In all three cases, the lesions were unilateral and localized, with limited extension into the sinonasal region, and they were not associated with malignancy or recurrent (as proved by endoscopy, computed tomography, and histopathologic examination). Total removal of the mass was achieved through a conservative intranasal approach. Endoscopic follow-up for periods ranging between 12 and 39 months, with an average of 23 months, failed to identify any recurrence. These findings point to the feasibility of applying this conservative endoscopic approach for total excision of limited lesions of inverted papilloma.

Entities:  

Mesh:

Year:  1992        PMID: 1637543     DOI: 10.1001/archotol.1992.01880060099020

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  3 in total

1.  Sinonasal inverted schneiderian papilloma presenting as a large intraoral lesion.

Authors:  Kumar Nilesh; Srijon Mukherji; Sujata R Kanetkar; Aaditee Vande
Journal:  BMJ Case Rep       Date:  2020-07-05

2.  A miniature robotic steerable endoscope for maxillary sinus surgery called PliENT.

Authors:  Julie Legrand; Mouloud Ourak; Laura Van Gerven; Vincent Vander Poorten; Emmanuel Vander Poorten
Journal:  Sci Rep       Date:  2022-02-10       Impact factor: 4.379

3.  Intranasal endoscopic prelacrimal recess approach for maxillary sinus inverted papilloma.

Authors:  Qian-Qian Yu; Ge Guan; Nian-Kai Zhang; Xiao-Wen Zhang; Yan Jiang; Yuan-Yuan Lian; Ting-Ting Liu; Xiao-Dan Jiang; Na Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-04       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.